These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 2088187

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. The activity of metal compounds against aerobic and anaerobic bacteria.
    Chin N, Neu HC.
    Diagn Microbiol Infect Dis; 1992 Aug; 15(6):549-52. PubMed ID: 1424509
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. In vitro activity of the new fluoroquinolone CP-99,219.
    Neu HC, Chin NX.
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2615-22. PubMed ID: 7872757
    [Abstract] [Full Text] [Related]

  • 45. Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.
    Arpi M, Gahrn-Hansen B, Søgaard P, Bentzon MW.
    Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):141-6. PubMed ID: 3473910
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Antimicrobial activity of DV-7751a, a new fluoroquinolone.
    Tanaka M, Hoshino K, Ishida H, Sato K, Hayakawa I, Osada Y.
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2112-8. PubMed ID: 8257132
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. In vitro antimicrobial activity and postantibiotic effect of lomefloxacin, a new difluoroquinolone.
    Molinari G, Bandelloni R, Paglia P, Debbia E, Schito GC.
    Diagn Microbiol Infect Dis; 1989 Oct; 12(3 Suppl):53S-56S. PubMed ID: 2791499
    [Abstract] [Full Text] [Related]

  • 50. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.
    Sato K, Hoshino K, Tanaka M, Hayakawa I, Osada Y.
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1491-8. PubMed ID: 1324647
    [Abstract] [Full Text] [Related]

  • 51. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
    Dholakia N, Rolston KV, Ho DH, LeBlanc B, Bodey GP.
    Antimicrob Agents Chemother; 1994 Apr; 38(4):848-52. PubMed ID: 8031057
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent.
    Eliopoulos GM, Klimm K, Rice LB, Ferraro MJ, Moellering RC.
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1154-9. PubMed ID: 2393275
    [Abstract] [Full Text] [Related]

  • 59. In vitro activity of lomefloxacin, a difluorinated quinolone, compared with other antimicrobials.
    Qadri SM, Lee GC, Ellis ME.
    Chemotherapy; 1991 Jun; 37(3):166-74. PubMed ID: 1889304
    [Abstract] [Full Text] [Related]

  • 60. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    Bauernfeind A.
    J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.